Bayer CEO speaks out on NICE's rejecton of anticancer drug
18 May 2009
Elizabeth Sukkar
Arthur Higgins, CEO of Bayer Healthcare, has criticised a recent preliminary decision by the UK's National Institute for health and Clinical Excellence (NICE), which rejected his firm's anticancer product Nexavar (sorafenib) for use on the national health service (NHS).
...
Please Login to read the full article.
18 May 2009
Elizabeth Sukkar
...
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE no for Tyverb and Herceptin in breast cancer, Roche considers appeal
- NICE "wasting a generation of anticancers" claims Pierre-Fabre in Javlor appeal
- Broad swathe of measures to support UK life sciences draws widespread applause
- "Step change" Yervoy from BMS not cost effective for NICE: may need biomarker test
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
